Compare
PharmaCyte Biotech, Inc. vs Amgen Inc vs Repligen Corp vs Champions Oncology, Inc.
| Latest fiscal year | PharmaCyte Biotech, Inc. PMCB | Amgen Inc AMGN | Repligen Corp RGEN | Champions Oncology, Inc. CSBR |
|---|---|---|---|---|
| Year ended | 2026-04-30 | 2025-12-31 | 2025-12-31 | 2026-04-30 |
| Revenue | $0 | $36.75B | $738.26M | $59.42M |
| Revenue growth (YoY) | n/a | +10.0% | +16.4% | +4.4% |
| Gross margin | n/a | 67.2% (computed) | 52.3% (computed) | 48.0% (computed) |
| Operating margin | n/a | 24.7% | 7.5% | -1.9% |
| Net margin | n/a | 21.0% | 6.6% | -2.0% |
| Net income | -$19.42M | $7.71B | $48.89M | -$1.18M |
| EPS (Diluted) | -$2.77 | $14.23 | $0.86 | -$0.08 |
| Operating cash flow | -$5.15M | $9.96B | $117.42M | -$4.47M |
| Free cash flow | n/a | $8.10B | $93.90M | -$5.04M |
| Cash & equivalents | $18.60M | $9.13B | $566.02M | n/a |
| Total assets | $46.75M | $90.59B | $2.95B | $26.99M |
| Total liabilities | $11.77M | n/a | $843.57M | $22.92M |
| Shareholders' equity | $33.29M | $8.66B | $2.11B | $3.94M |
| Return on year-end equity | -58.3% | 89.1% | 2.3% | -29.8% |
| Shares outstanding | 10.74M | 538.80M | 56.33M | 13.89M |
Revenue, most recent five fiscal years
| Fiscal year | PharmaCyte Biotech, Inc. | Amgen Inc | Repligen Corp | Champions Oncology, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2026-04-30 | $36.75B Ended 2025-12-31 | $738.26M Ended 2025-12-31 | $59.42M Ended 2026-04-30 |
| 1 year earlier | $0 Ended 2025-04-30 | $33.42B Ended 2024-12-31 | $634.44M Ended 2024-12-31 | $56.94M Ended 2025-04-30 |
| 2 years earlier | $0 Ended 2024-04-30 | $28.19B Ended 2023-12-31 | $632.36M Ended 2023-12-31 | $50.16M Ended 2024-04-30 |
| 3 years earlier | $0 Ended 2023-04-30 | $26.32B Ended 2022-12-31 | $801.54M Ended 2022-12-31 | $53.87M Ended 2023-04-30 |
| 4 years earlier | $0 Ended 2022-04-30 | $25.98B Ended 2021-12-31 | $670.53M Ended 2021-12-31 | $49.11M Ended 2022-04-30 |